CN102149702A - 新型亚甲二氧基酚化合物和其治疗疾病的用途 - Google Patents

新型亚甲二氧基酚化合物和其治疗疾病的用途 Download PDF

Info

Publication number
CN102149702A
CN102149702A CN2009801354528A CN200980135452A CN102149702A CN 102149702 A CN102149702 A CN 102149702A CN 2009801354528 A CN2009801354528 A CN 2009801354528A CN 200980135452 A CN200980135452 A CN 200980135452A CN 102149702 A CN102149702 A CN 102149702A
Authority
CN
China
Prior art keywords
inv
compound
composition
carbons
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801354528A
Other languages
English (en)
Chinese (zh)
Inventor
S·帕萨沙拉蒂
S·拉杰高波兰
D·拉贾格帕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invasc Therapeutics Inc
Ohio State University Research Foundation
Original Assignee
Invasc Therapeutics Inc
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invasc Therapeutics Inc, Ohio State University Research Foundation filed Critical Invasc Therapeutics Inc
Publication of CN102149702A publication Critical patent/CN102149702A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CN2009801354528A 2008-08-05 2009-08-05 新型亚甲二氧基酚化合物和其治疗疾病的用途 Pending CN102149702A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8642508P 2008-08-05 2008-08-05
US61/086,425 2008-08-05
PCT/US2009/052893 WO2010017323A1 (en) 2008-08-05 2009-08-05 Novel methylenedioxy phenolic compounds and their use to treat disease

Publications (1)

Publication Number Publication Date
CN102149702A true CN102149702A (zh) 2011-08-10

Family

ID=41172398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801354528A Pending CN102149702A (zh) 2008-08-05 2009-08-05 新型亚甲二氧基酚化合物和其治疗疾病的用途

Country Status (11)

Country Link
US (2) US8198317B2 (https=)
EP (1) EP2324005A1 (https=)
JP (1) JP2011530525A (https=)
KR (1) KR20110042108A (https=)
CN (1) CN102149702A (https=)
AU (1) AU2009279667A1 (https=)
BR (1) BRPI0917262A2 (https=)
CA (1) CA2733430A1 (https=)
IL (1) IL211076A0 (https=)
RU (1) RU2011108587A (https=)
WO (1) WO2010017323A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110305102A (zh) * 2019-08-13 2019-10-08 陕西中医药大学 1,3-苯并二噁茂天然多酚酸酯类化合物及其降血脂应用
CN112745291A (zh) * 2019-10-29 2021-05-04 浙江大学宁波理工学院 一种具有HMG-CoA还原酶抑制活性的化合物、药物组合物及应用
CN115047092A (zh) * 2022-04-07 2022-09-13 济宁医学院 一种血管紧张素转移酶ii抑制剂的筛选方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120129818A1 (en) * 2009-04-23 2012-05-24 Desikan Rajagopal Compositions and Methods for Treatment of Cardiovascular Disease
CN106957298B (zh) * 2017-04-18 2019-07-16 湖南中医药大学 一种硫辛酸苯酚酯衍生物及其制备方法和应用
US11306076B2 (en) * 2020-05-11 2022-04-19 Xi'an Taikomed Pharmaceutical Technology Co., Ltd. Silibinin lipoic acid ester with hepatoprotective activity and a method of preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031275A1 (en) * 1998-02-09 2001-10-18 Forse R Armour Sesamol inhibitor of delta-5-desaturase activity and uses therefor
ATE305467T1 (de) 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
ES2239203T3 (es) * 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110305102A (zh) * 2019-08-13 2019-10-08 陕西中医药大学 1,3-苯并二噁茂天然多酚酸酯类化合物及其降血脂应用
CN110305102B (zh) * 2019-08-13 2020-11-24 陕西中医药大学 1,3-苯并二噁茂天然多酚酸酯类化合物及其降血脂应用
CN112745291A (zh) * 2019-10-29 2021-05-04 浙江大学宁波理工学院 一种具有HMG-CoA还原酶抑制活性的化合物、药物组合物及应用
CN115047092A (zh) * 2022-04-07 2022-09-13 济宁医学院 一种血管紧张素转移酶ii抑制剂的筛选方法
CN115047092B (zh) * 2022-04-07 2023-10-20 济宁医学院 一种血管紧张素转移酶ii抑制剂的筛选方法

Also Published As

Publication number Publication date
AU2009279667A1 (en) 2010-02-11
KR20110042108A (ko) 2011-04-22
EP2324005A1 (en) 2011-05-25
US20100035849A1 (en) 2010-02-11
BRPI0917262A2 (pt) 2015-11-10
JP2011530525A (ja) 2011-12-22
US20130157986A1 (en) 2013-06-20
CA2733430A1 (en) 2010-02-11
US8198317B2 (en) 2012-06-12
RU2011108587A (ru) 2012-09-10
WO2010017323A1 (en) 2010-02-11
IL211076A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
JP7058610B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールの中鎖脂肪酸エステル並びに組成物、並びにそれを使用するための方法
AU2018392987A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
CA2889892A1 (en) Alternative uses for hbv assembly effectors
CN102149702A (zh) 新型亚甲二氧基酚化合物和其治疗疾病的用途
CZ330896A3 (cs) Použití látky, která brání nebo minimalizuje oxidaci polynenasycené mastné kyseliny a způsoby s tímto použitím spojené
KR20090010035A (ko) 물질대사 장애의 치료용 화합물
KR20020010581A (ko) 핵수용체 ｐｐａｒ의 신규한 리간드
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2020132378A2 (en) Compositions and methods of treatment for neurological disorders comprising depression
JP2023033425A (ja) がん、糖尿病および神経障害の処置のための新規スピロおよび環式ビス－ベンジリジンプロテアソーム阻害剤
JPH085780B2 (ja) 変形性関節症治療剤
EP1746982A2 (en) Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis and cardiovascular diseases
WO2025118341A1 (zh) 一种肉桂酸衍生物及其制备方法与应用
EP1686979A2 (en) Activation of hypoxia-inducible gene expression
CN113181160A (zh) 异硫氰酸酯类化合物的用途
CN119350175B (zh) 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途
CN113912594B (zh) 硝基噻吩甲胺类光学异构体及其医药用途
JP2009191041A (ja) ヒドロキシメチルケトン誘導体
CN114409597A (zh) 一种青藤碱衍生物及其制备方法与应用
WO2006132196A1 (ja) β３作動薬を含有する新規な医薬
Bai et al. (−)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds inducing the formation of morphologically similar tubulin spirals but binding apparently to two distinct sites on tubulin
JP2003335680A (ja) Ａｃａｔ−１阻害剤
JPH0680582A (ja) 脂質代謝改善剤
US9522139B2 (en) Fructose 1, 6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis
Geerts et al. Screening of Trichostatin Analogues Based on Cellular Potency in the Murine Multiple Myeloma 5T33MM Model

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110810